Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

US Oncology Network

7 abstracts

Abstract
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
Org: Yale Cancer Center, Yale School of Medicine, Emory University School of Medicine, Nashville Breast Center, Dallas Surgical Group,
Abstract
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fox Chase Cancer Center, David Geffen School of Medicine at UCLA, Winship Cancer Institute at Emory University, Georgetown University Medical School,
Abstract
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.
Org: US Oncology Network/Virginia Oncology Associates, Ontada, US Oncology Network, Virginia Cancer Specialists, US Oncology Network / Virginia Oncology Associates,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).
Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
Org: Virginia Cancer Specialists, US Oncology Network, Mirati Therapeutics, Ontada,
Abstract
The impact of a cancer-specific novel therapy adjustment (NTA) in Medicare value-based care programs: A simulation exercise.
Org: US Oncology Network, Dallas, Txinno Bioscience, McKesson, Denver, CO,
Abstract
Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC).
Org: US Oncology Network, New York Oncology Hematology PC, Ontada,